• Haryani Haryani, Susan Jane Fetzer, Ching-Lin Wu, and Yu-Yun Hsu.
• Universitas Gadjah Mada.
• Oncol Nurs Forum. 2017 May 1; 44 (3): E111-E123.

Problem IdentificationChemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting chemotherapy toxicity, which has a long-lasting effect and decreases quality of life. Although several tools have been developed to detect CIPN, the study quality, psychometric properties, and practicality of CIPN assessment tools have not been systematically reviewed.
.Literature SearchElectronic searches using keywords were conducted in Medline, PubMed, CINAHL®, and Cochrane Library for articles published from 1980-2015. Eligible studies were included if they involved patients with cancer receiving chemotherapy, provided CIPN assessment tools with psychometric properties, and were published in English.
.Data EvaluationData were extracted, and study quality was assessed. CIPN tools were evaluated in terms of psychometric properties and practicality.
.SynthesisA total of 19 studies describing 20 tools were reviewed. The quality of studies varied from strong to weak. The validity ranged from low to high, and the reliability with internal consistency ranged from 0.56-0.96. Poor inter-rater agreement was found. Not all of the tools were deemed practical.
.ConclusionsConsidering the psychometric properties and practicality, two tools (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-Ntx] and Total Neuropathy Score [TNS]) are recommended for assessing CIPN.
.Implications For NursingRoutine assessment of CIPN and choosing appropriate assessment tools are imperative. The FACT/GOG-Ntx and TNS are recommended for clinical use.

22 keywords...

hide…